Patents by Inventor Thomas Langer

Thomas Langer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200261542
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Application
    Filed: January 24, 2020
    Publication date: August 20, 2020
    Inventors: Britta GÖBEL, Mark SOMMERFELD, Oliver BOSCHEINEN, Thomas LANGER, Christine RUDOLPH, Andreas EVERS
  • Publication number: 20200255540
    Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Application
    Filed: December 23, 2019
    Publication date: August 13, 2020
    Inventors: Christian Beil, Karl-Christian Engel, Gerhard Hessler, Soraya Hoelper, Christian Lange, Thomas Langer, Cendrine Lemoine, Wulf-Dirk Leuschner, Sevim Oezguer Bruederle, Ercole Rao, Nadja Spindler, Sandra Weil
  • Publication number: 20200228562
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Publication number: 20200220895
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely collects system information from computers across the enterprise, internally encrypts and analyzes the collected information for indicators of compromise, threatening behavior, and known vulnerabilities, and generates alerts regarding known and potential threats for further analysis and remediation. If potential threats are identified, the system may deploy a memory analysis module that takes a deeper analysis of the potentially compromised computer to obtain more information about the potential threat.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 10609065
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 31, 2020
    Assignee: KIVU CONSULTING, INC.
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 10594719
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely collects system information from computers across the enterprise, internally encrypts and analyzes the collected information for indicators of compromise, threatening behavior, and known vulnerabilities, and generates alerts regarding known and potential threats for further analysis and remediation. If potential threats are identified, the system may deploy a memory analysis module that takes a deeper analysis of the potentially compromised computer to obtain more information about the potential threat.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 17, 2020
    Assignee: Kivu Consulting, Inc.
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 10583174
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 10, 2020
    Assignee: SANOFI
    Inventors: Britta Göbel, Mark Sommerfeld, Oliver Boscheinen, Thomas Langer, Christine Rudolph, Andreas Evers
  • Publication number: 20190100498
    Abstract: The application relates to a crystalline form of the compound of formula (I).
    Type: Application
    Filed: March 24, 2016
    Publication date: April 4, 2019
    Inventors: Thomas LANGER, Paul Allen BETHEL, Mohammed PERVEZ, Lai Chun CHAN, Sophie JANBON
  • Publication number: 20190085043
    Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.
    Type: Application
    Filed: July 27, 2018
    Publication date: March 21, 2019
    Inventors: Oliver Boscheinen, Matthias Dreyer, Paul Habermann, Hans-Ludwig Schaefer, Mark Sommerfeld, Thomas Langer
  • Publication number: 20180371041
    Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 27, 2018
    Inventors: Mark SOMMERFELD, Thomas LANGER, Oliver BOSCHEINEN, Matthias DREYER, Werner DITTRICH, Paul HABERMANN
  • Publication number: 20180236037
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 23, 2018
    Inventors: Britta GÖBEL, Mark SOMMERFELD, Oliver BOSCHEINEN, Thomas LANGER, Christine RUDOLPH, Andreas EVERS
  • Patent number: 9975881
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 22, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Publication number: 20180063182
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Publication number: 20180057567
    Abstract: Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Inventors: Ercole Rao, Christian Beil, Christian Lange, Katja Kroll, Wulf-Dirk Leuschner, Ingo Focken, Thomas Langer, Nadja Spindler
  • Publication number: 20180063181
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely collects system information from computers across the enterprise, internally encrypts and analyzes the collected information for indicators of compromise, threatening behavior, and known vulnerabilities, and generates alerts regarding known and potential threats for further analysis and remediation. If potential threats are identified, the system may deploy a memory analysis module that takes a deeper analysis of the potentially compromised computer to obtain more information about the potential threat.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 9458954
    Abstract: A double-wall pipe for a transportation means which includes an outer pipe and an inner pipe extending therein. The outer pipe has two pipe segments which are formed like half-shells and are joined together to form the outer pipe along the longitudinal edges thereof. In this way, it is possible to make both the outer pipe and the inner pipe of metal, such that the wall thickness of the inner pipe can be relatively small.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: October 4, 2016
    Assignee: AIRBUS OPERATIONS GMBH
    Inventors: Alexander Baur, Christoph Heimerdinger, Roland Lang, Thomas Langer, Heinz Meister, Josef Messner, Dirk Schwarze
  • Patent number: 9441040
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 13, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Publication number: 20160194371
    Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 7, 2016
    Inventors: Oliver Boscheinen, Matthias Dreyer, Paul Habermann, Hans-Ludwig Schaefer, Mark Sommerfeld, Thomas Langer
  • Publication number: 20160108023
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Patent number: 9221782
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: December 29, 2015
    Assignee: AstraZeneca AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams